{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T18:04:57Z","timestamp":1786125897173,"version":"build-2736575974"},"reference-count":146,"publisher":"Mattioli1885","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Introduction: Psoriasis and atopic dermatitis are leading examples of chronic inflammatory dermatoses with distinct clinical manifestations, pathogenesis, and demographic patterns. However, recent research has revealed overlapping immunological pathways that could serve as promising therapeutic targets. Objectives: To synthesize the principal immunological, epidermal barrier, and microbiome pathways shared by psoriasis and atopic dermatitis and to discuss their potential translational and therapeutic implications. Methods: We conducted a narrative review of the literature on PubMed from January 2000 to June 2024, using keywords such as \u201cpsoriasis,\u201d \u201catopic dermatitis,\u201d \u201ccytokine pathways,\u201d \u201cT cells,\u201d and \u201cenvironmental triggers.\u201d Studies were selected based on their relevance to shared mechanisms between these diseases, focusing on cytokine profiles, immune cell activity, and skin barrier dysfunction. Results: Our review identified significant overlaps in cytokine-mediated pathways, particularly the IL-17\/IL-22 axis, which mediates keratinocyte hyperproliferation and inflammation in both diseases. T cell dysregulation, including Th17 and Th22 activity, plays a pivotal role in maintaining chronic inflammation. Both conditions also exhibit impaired skin barrier function, linked to filaggrin loss-of-function mutations in atopic dermatitis and abnormal keratinocyte differentiation in psoriasis. Conclusion: These findings suggest that targeting shared mechanisms, such as the Th17 and Th22 pathways, along with barrier repair strategies may enable dual therapeutic benefits. This review underscores the potential for integrative treatment approaches and personalized medicine in managing chronic inflammatory skin disorders.<\/jats:p>","DOI":"10.5826\/dpc.1603a6662","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:07:47Z","timestamp":1785510467000},"page":"6662","source":"Crossref","is-referenced-by-count":0,"title":["Shared Pathways between Psoriasis and Atopic Dermatitis"],"prefix":"10.5826","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9092-6183","authenticated-orcid":false,"given":"Federica","family":"Trovato","sequence":"first","affiliation":[{"name":"Dermatology Unit, Department of Medical and Cardiovascular sciences, Sapienza University, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Chello","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical and Cardiovascular sciences, Sapienza University, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Amato","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical and Cardiovascular sciences, Sapienza University, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Guardo","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Istituto Dermopatico dell\u2019Immacolata IDI-IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Amore","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical and Cardiovascular sciences, Sapienza University, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Bennardo","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical and Cardiovascular sciences, Sapienza University, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Giovanni","family":"Richetta","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical and Cardiovascular sciences, Sapienza University, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Grieco","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical and Cardiovascular sciences, Sapienza University, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Paul","family":"Nistico","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical and Cardiovascular sciences, Sapienza University, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pellacani","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical and Cardiovascular sciences, Sapienza University, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annunziata","family":"Dattola","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical and Cardiovascular sciences, Sapienza University, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27750","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"10.5826\/dpc.1603a6662_ref1","doi-asserted-by":"crossref","unstructured":"Boehncke WH, Sch\u00f6n MP. Psoriasis. Lancet. 2015;386-983-994.","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"10.5826\/dpc.1603a6662_ref2","doi-asserted-by":"crossref","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397:1301-1315.","DOI":"10.1016\/S0140-6736(20)32549-6"},{"key":"10.5826\/dpc.1603a6662_ref3","doi-asserted-by":"crossref","unstructured":"Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263-271.","DOI":"10.1016\/S0140-6736(07)61128-3"},{"key":"10.5826\/dpc.1603a6662_ref4","unstructured":"Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study - PubMed. Accessed June 23, 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/37705227\/"},{"key":"10.5826\/dpc.1603a6662_ref5","doi-asserted-by":"crossref","unstructured":"Ilaria P, Ersilia T, Nicoletta B, et al. The Role of the Western Diet on Atopic Dermatitis: Our Experience and Review of the Current Literature. Nutrients. 2023;15(18):3896.","DOI":"10.3390\/nu15183896"},{"key":"10.5826\/dpc.1603a6662_ref6","doi-asserted-by":"crossref","unstructured":"Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: Clinical implications. Allergy Asthma Proc. 2019;40(2):84-92.","DOI":"10.2500\/aap.2019.40.4202"},{"key":"10.5826\/dpc.1603a6662_ref7","doi-asserted-by":"crossref","unstructured":"Dong S, Li D, Shi D. Skin barrier-inflammatory pathway is a driver of the psoriasis-atopic dermatitis transition. Front Med. 2024;11.","DOI":"10.3389\/fmed.2024.1335551"},{"key":"10.5826\/dpc.1603a6662_ref8","doi-asserted-by":"crossref","unstructured":"Barry K, Zancanaro P, Casseres R, Abdat R, Dumont N, Rosmarin D. Concomitant atopic dermatitis and psoriasis - a retrospective review. J Dermatolog Treat. 2021;32(7):716-720.","DOI":"10.1080\/09546634.2019.1702147"},{"key":"10.5826\/dpc.1603a6662_ref9","doi-asserted-by":"crossref","unstructured":"Abramovits W, Cockerell C, Stevenson LC, Goldstein AM, Ehrig T, Menter A. PsEma--a hitherto unnamed dermatologic entity with clinical features of both psoriasis and eczema. Skinmed. 2005;4(5):275-281.","DOI":"10.1111\/j.1540-9740.2005.03636.x"},{"key":"10.5826\/dpc.1603a6662_ref10","doi-asserted-by":"crossref","unstructured":"Aydin O, Engin B, O\u011fuz O, Ilvan S, Demirkesen C. Non-pustular palmoplantar psoriasis: is histologic differentiation from eczematous dermatitis possible? J Cutan Pathol. 2008;35(2):169-173.","DOI":"10.1111\/j.1600-0560.2007.00782.x"},{"key":"10.5826\/dpc.1603a6662_ref11","unstructured":"Davis KL, Claudio-Etienne E, Frischmeyer-Guerrerio PA. Atopic Dermatitis and Food Allergy: More Than Sensitization. Mucosal Immunol. Published online June 19, 2024:S1933-0219(24)00059-X."},{"key":"10.5826\/dpc.1603a6662_ref12","doi-asserted-by":"crossref","unstructured":"Bellinato F, Gisondi P, Balato A, et al. Awareness of obesity among patients with psoriasis. J Eur Acad Dermatol Venereol. 2024;38(5):e391-e393.","DOI":"10.1111\/jdv.19617"},{"key":"10.5826\/dpc.1603a6662_ref13","doi-asserted-by":"crossref","unstructured":"Bentz P, Eyerich K, Skudlik C, et al. [Hand eczema or psoriasis: update on the FB 323 study occupational dermatology cohort]. Dermatologie (Heidelb). 2023;74(6):402-409.","DOI":"10.1007\/s00105-023-05156-z"},{"key":"10.5826\/dpc.1603a6662_ref14","doi-asserted-by":"crossref","unstructured":"Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840-848.","DOI":"10.1111\/bjd.18245"},{"key":"10.5826\/dpc.1603a6662_ref15","doi-asserted-by":"crossref","unstructured":"Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: Implications for management. J Am Acad Dermatol. 2017;76(3):393-403.","DOI":"10.1016\/j.jaad.2016.07.065"},{"key":"10.5826\/dpc.1603a6662_ref16","doi-asserted-by":"crossref","unstructured":"Messina F, Valenti M, Malagoli P, et al. Early predictors of psoriatic arthritis: a Delphi-based consensus from Italian dermatology centers. Ital J Dermatol Venerol. 2022;157(3):231-234.","DOI":"10.23736\/S2784-8671.21.07203-0"},{"key":"10.5826\/dpc.1603a6662_ref17","doi-asserted-by":"crossref","unstructured":"Dattola A, Bernardini N, Anedda J, et al. The role of guselkumab in psoriatic artrithis and disease progression in patients with confirmed diagnosis of enthesitis. Ital J Dermatol Venerol. Published online June 3, 2024.","DOI":"10.23736\/S2784-8671.24.07921-0"},{"key":"10.5826\/dpc.1603a6662_ref18","doi-asserted-by":"crossref","unstructured":"Campione E, Mazzilli S, Di Prete M, et al. The Role of Glutathione-S Transferase in Psoriasis and Associated Comorbidities and the Effect of Dimethyl Fumarate in This Pathway. Front Med (Lausanne). 2022;9:760852.","DOI":"10.3389\/fmed.2022.760852"},{"key":"10.5826\/dpc.1603a6662_ref19","doi-asserted-by":"crossref","unstructured":"Song WB, Soffer DE, Gelfand JM. Using Guidelines of Care to Lower Cardiovascular Risk in Patients with Psoriasis. Dermatol Clin. 2024;42(3):417-428.","DOI":"10.1016\/j.det.2024.02.008"},{"key":"10.5826\/dpc.1603a6662_ref20","doi-asserted-by":"crossref","unstructured":"Yang X, Cheng J, Yin X, et al. Metabolic Profiling for Unveiling Mechanisms of Kushenol F against Imiquimod-Induced Psoriasis with UHPLC\/MS Analysis. Molecules. 2024;29(11):2410.","DOI":"10.3390\/molecules29112410"},{"key":"10.5826\/dpc.1603a6662_ref21","unstructured":"AlShobaili HA, Shahzad M, Al-Marshood A, Khalil A, Settin A, Barrimah I. Genetic Background of Psoriasis. Int J Health Sci (Qassim). 2010;4(1):23-29."},{"key":"10.5826\/dpc.1603a6662_ref22","doi-asserted-by":"crossref","unstructured":"Elder JT, Henseler T, Christophers E, Voorhees JJ, Nair RP. Of genes and antigens: the inheritance of psoriasis. J Invest Dermatol. 1994;103(5 Suppl):150S-153S.","DOI":"10.1111\/1523-1747.ep12399486"},{"key":"10.5826\/dpc.1603a6662_ref23","unstructured":"Queiro R, Torre JC, Gonz\u00e1lez S, L\u00f3pez-Larrea C, Tintur\u00e9 T, L\u00f3pez-Lagunas I. HLA antigens may influence the age of onset of psoriasis and psoriatic arthritis. J Rheumatol. 2003;30(3):505-507."},{"key":"10.5826\/dpc.1603a6662_ref24","doi-asserted-by":"crossref","unstructured":"Duffy DL, Spelman LS, Martin NG. Psoriasis in Australian twins. J Am Acad Dermatol. 1993;29(3):428-434.","DOI":"10.1016\/0190-9622(93)70206-9"},{"key":"10.5826\/dpc.1603a6662_ref25","doi-asserted-by":"crossref","unstructured":"Generali E, Ceribelli A, Stazi MA, Selmi C. Lessons learned from twins in autoimmune and chronic inflammatory diseases. J Autoimmun. 2017;83:51-61. d","DOI":"10.1016\/j.jaut.2017.04.005"},{"key":"10.5826\/dpc.1603a6662_ref26","doi-asserted-by":"crossref","unstructured":"Enlund F, Samuelsson L, Enerb\u00e4ck C, et al. Analysis of three suggested psoriasis susceptibility loci in a large Swedish set of families: confirmation of linkage to chromosome 6p (HLA region), and to 17q, but not to 4q. Hum Hered. 1999;49(1):2-8.","DOI":"10.1159\/000022832"},{"key":"10.5826\/dpc.1603a6662_ref27","unstructured":"The Genetic Susceptibility to Psoriasis and the Relationship of Linked Genes to Our Treatment Options - PubMed. Accessed June 25, 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/37569685\/"},{"key":"10.5826\/dpc.1603a6662_ref28","doi-asserted-by":"crossref","unstructured":"International Psoriasis Genetics Consortium. The International Psoriasis Genetics Study: assessing linkage to 14 candidate susceptibility loci in a cohort of 942 affected sib pairs. Am J Hum Genet. 2003;73(2):430-437.","DOI":"10.1086\/377159"},{"key":"10.5826\/dpc.1603a6662_ref29","doi-asserted-by":"crossref","unstructured":"Singh S, Pradhan D, Puri P, et al. Genomic alterations driving psoriasis pathogenesis. Gene. 2019;683:61-71.","DOI":"10.1016\/j.gene.2018.09.042"},{"key":"10.5826\/dpc.1603a6662_ref30","doi-asserted-by":"crossref","unstructured":"Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years\u2019 experience with low-dose long-term treatment. Journal of the European Academy of Dermatology and Venereology. 2000;14(5):382-388.","DOI":"10.1046\/j.1468-3083.2000.00058.x"},{"key":"10.5826\/dpc.1603a6662_ref31","doi-asserted-by":"crossref","unstructured":"Alabas OA, Mason KJ, Yiu ZZN, et al. The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2024;190(5):689-700.","DOI":"10.1093\/bjd\/ljad481"},{"key":"10.5826\/dpc.1603a6662_ref32","doi-asserted-by":"crossref","unstructured":"Queiro R, Bra\u00f1a I, Pardo E, et al. Influence of the HLA-Cw6 Allele and IFIH1\/MDA5 Gene Variants on the Cardiometabolic Risk Profile of Patients with Psoriatic Disease. J Clin Med. 2024;13(3):845.","DOI":"10.3390\/jcm13030845"},{"key":"10.5826\/dpc.1603a6662_ref33","doi-asserted-by":"crossref","unstructured":"Alsabbagh MM. Cytokines in psoriasis: From pathogenesis to targeted therapy. Hum Immunol. 2024;85(4):110814.","DOI":"10.1016\/j.humimm.2024.110814"},{"key":"10.5826\/dpc.1603a6662_ref34","doi-asserted-by":"crossref","unstructured":"Liu XL, Chang LS. Deciphering the Genetic Links between Psychological Stress, Autophagy, and Dermatological Health: Insights from Bioinformatics, Single-Cell Analysis, and Machine Learning in Psoriasis and Anxiety Disorders. Int J Mol Sci. 2024;25(10):5387.","DOI":"10.3390\/ijms25105387"},{"key":"10.5826\/dpc.1603a6662_ref35","doi-asserted-by":"crossref","unstructured":"Lanna C, Lambiase S, Gaeta Shumak R, et al. Why targeted therapeutics have provided benefit in psoriasis: looking at IL-17 biology. Expert Rev Clin Pharmacol. 2022;15(10):1209-1224.","DOI":"10.1080\/17512433.2022.2130758"},{"key":"10.5826\/dpc.1603a6662_ref36","unstructured":"Szczerkowska-Dobosz A, Placek W, Szczerkowska Z, Roszkiewicz J. Psoriasis vulgaris with the early and late onset--HLA phenotype correlations. Arch Immunol Ther Exp (Warsz). 1996;44(4):265-269."},{"key":"10.5826\/dpc.1603a6662_ref37","doi-asserted-by":"crossref","unstructured":"Jordan CT, Cao L, Roberson EDO, et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet. 2012;90(5):784-795.","DOI":"10.1016\/j.ajhg.2012.03.012"},{"key":"10.5826\/dpc.1603a6662_ref38","doi-asserted-by":"crossref","unstructured":"Bian S, Zhang L, Duan L, Wang X, Min Y, Yu H. Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model. J Mol Med (Berl). 2014;92(4):387-397.","DOI":"10.1007\/s00109-013-1110-5"},{"key":"10.5826\/dpc.1603a6662_ref39","doi-asserted-by":"crossref","unstructured":"Matthews D, Fry L, Powles A, et al. Evidence that a locus for familial psoriasis maps to chromosome 4q. Nat Genet. 1996;14(2):231-233. doi:10.1038\/ng1096-231","DOI":"10.1038\/ng1096-231"},{"key":"10.5826\/dpc.1603a6662_ref40","doi-asserted-by":"crossref","unstructured":"Caruso R, Botti E, Sarra M, et al. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med. 2009;15(9):1013-1015.","DOI":"10.1038\/nm.1995"},{"key":"10.5826\/dpc.1603a6662_ref41","doi-asserted-by":"crossref","unstructured":"Han D, Li F, Zhao Y, et al. IL-21 promoting angiogenesis contributes to the development of psoriasis. FASEB J. 2024;38(1):e23375.","DOI":"10.1096\/fj.202201709RRRR"},{"key":"10.5826\/dpc.1603a6662_ref42","doi-asserted-by":"crossref","unstructured":"H\u00fcffmeier U, Estivill X, Riveira-Munoz E, et al. Deletion of LCE3C and LCE3B genes at PSORS4 does not contribute to susceptibility to psoriatic arthritis in German patients. Ann Rheum Dis. 2010;69(5):876-878.","DOI":"10.1136\/ard.2009.108951"},{"key":"10.5826\/dpc.1603a6662_ref43","doi-asserted-by":"crossref","unstructured":"Wolf R, Orion E, Ruocco E, Ruocco V. Abnormal epidermal barrier in the pathogenesis of psoriasis. Clin Dermatol. 2012;30(3):323-328.","DOI":"10.1016\/j.clindermatol.2011.08.022"},{"key":"10.5826\/dpc.1603a6662_ref44","doi-asserted-by":"crossref","unstructured":"Capon F, Semprini S, Chimenti S, et al. Fine mapping of the PSORS4 psoriasis susceptibility region on chromosome 1q21. J Invest Dermatol. 2001;116(5):728-730. doi:10.1046\/j.1523-1747.2001.01311.x","DOI":"10.1046\/j.1523-1747.2001.01311.x"},{"key":"10.5826\/dpc.1603a6662_ref45","doi-asserted-by":"crossref","unstructured":"Samuelsson L, Stiller C, Friberg C, Nilsson C, Inerot A, Wahlstr\u00f6m J. Association analysis of cystatin A and zinc finger protein 148, two genes located at the psoriasis susceptibility locus PSORS5. J Invest Dermatol. 2004;122(6):1399-1400.","DOI":"10.1046\/j.0022-202X.2004.12604.x"},{"key":"10.5826\/dpc.1603a6662_ref46","doi-asserted-by":"crossref","unstructured":"Vasilopoulos Y, Walters K, Cork MJ, Duff GW, Sagoo GS, Tazi-Ahnini R. Association analysis of the skin barrier gene cystatin A at the PSORS5 locus in psoriatic patients: evidence for interaction between PSORS1 and PSORS5. Eur J Hum Genet. 2008;16(8):1002-1009.","DOI":"10.1038\/ejhg.2008.40"},{"key":"10.5826\/dpc.1603a6662_ref47","unstructured":"Keratolinin: the soluble substrate of epidermal transglutaminase from human and bovine tissue. | PNAS. Accessed July 7, 2024. https:\/\/www.pnas.org\/doi\/abs\/10.1073\/pnas.81.1.238"},{"key":"10.5826\/dpc.1603a6662_ref48","doi-asserted-by":"crossref","unstructured":"H\u00fcffmeier U, Lascorz J, Becker T, et al. Characterisation of psoriasis susceptibility locus 6 (PSORS6) in patients with early onset psoriasis and evidence for interaction with PSORS1. J Med Genet. 2009;46(11):736-744.","DOI":"10.1136\/jmg.2008.065029"},{"key":"10.5826\/dpc.1603a6662_ref49","doi-asserted-by":"crossref","unstructured":"Zenz R, Eferl R, Kenner L, et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature. 2005;437(7057):369-375.","DOI":"10.1038\/nature03963"},{"key":"10.5826\/dpc.1603a6662_ref50","doi-asserted-by":"crossref","unstructured":"Lee YA, R\u00fcschendorf F, Windemuth C, et al. Genomewide scan in german families reveals evidence for a novel psoriasis-susceptibility locus on chromosome 19p13. Am J Hum Genet. 2000;67(4):1020-1024.","DOI":"10.1086\/303075"},{"key":"10.5826\/dpc.1603a6662_ref51","doi-asserted-by":"crossref","unstructured":"Alghamdi MA, Al-Eitan LN, Aljamal HA, Shati AA, Alshehri MA. Genetic association of IL2RA, IL17RA, IL23R, and IL31RA single nucleotide polymorphisms with alopecia areata. Saudi J Biol Sci. 2022;29(11):103460.","DOI":"10.1016\/j.sjbs.2022.103460"},{"key":"10.5826\/dpc.1603a6662_ref52","doi-asserted-by":"crossref","unstructured":"F\u0130L\u0130Z B, YILDIRIM M, HEK\u0130MLER \u00d6ZT\u00dcRK K, et al. Evaluation of interleukin-23 receptor (IL-23R) gene polymorphisms and serum IL-23 levels in patients with psoriasis. Turk J Med Sci. 2019;49(5):1386-1394.","DOI":"10.3906\/sag-1904-48"},{"key":"10.5826\/dpc.1603a6662_ref53","doi-asserted-by":"crossref","unstructured":"Di Meglio P, Villanova F, Napolitano L, et al. The IL23R A\/Gln381 Allele Promotes IL-23 Unresponsiveness in Human Memory T-Helper 17 Cells and Impairs Th17 Responses in Psoriasis Patients. J Invest Dermatol. 2013;133(10):2381-2389.","DOI":"10.1038\/jid.2013.170"},{"key":"10.5826\/dpc.1603a6662_ref54","doi-asserted-by":"crossref","unstructured":"Vasku V, Bienertova Vasku J, Slonkov\u00e1 V, Kankov\u00e1 K, Vasku A. Matrix metalloproteinase-2 promoter variability in psoriasis. Arch Dermatol Res. 2009;301(6):467-473.:","DOI":"10.1007\/s00403-009-0947-5"},{"key":"10.5826\/dpc.1603a6662_ref55","doi-asserted-by":"crossref","unstructured":"Zhu K, Yin X, Tang X, Zhang F, Yang S, Zhang X. Meta-analysis of NOD2\/CARD15 polymorphisms with psoriasis and psoriatic arthritis. Rheumatol Int. 2012;32(7):1893-1900.","DOI":"10.1007\/s00296-011-1813-2"},{"key":"10.5826\/dpc.1603a6662_ref56","doi-asserted-by":"crossref","unstructured":"Madan V, Ortiz-L\u00f3pez LI, Sakunchotpanit G, Chen R, Nayudu K, Nambudiri VE. Psoriasis in the Era of Targeted Cancer Therapeutics: A Systematic Review on De Novo and Pre-existing Psoriasis in Oncologic Patients Treated with Emerging Anti-neoplastic Agents. Dermatol Ther (Heidelb). Published online June 22, 2024.","DOI":"10.1007\/s13555-024-01198-w"},{"key":"10.5826\/dpc.1603a6662_ref57","doi-asserted-by":"crossref","unstructured":"Zhang XJ, Yan KL, Wang Z, et al. Polymorphisms in Interleukin-15 Gene on Chromosome 4q31.2 Are Associated with Psoriasis Vulgaris in Chinese Population. The Journal of investigative dermatology. 2007;127:2544-2551.","DOI":"10.1038\/sj.jid.5700896"},{"key":"10.5826\/dpc.1603a6662_ref58","doi-asserted-by":"crossref","unstructured":"Villadsen LS, Schuurman J, Beurskens F, et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest. 2003;112(10):1571-1580.","DOI":"10.1172\/JCI200318986"},{"key":"10.5826\/dpc.1603a6662_ref59","doi-asserted-by":"crossref","unstructured":"Fejza A, Camicia L, Carobolante G, et al. Emilin2 fosters vascular stability by promoting pericyte recruitment. Matrix Biology. 2023;122.","DOI":"10.1016\/j.matbio.2023.08.002"},{"key":"10.5826\/dpc.1603a6662_ref60","doi-asserted-by":"crossref","unstructured":"H\u00fcffmeier U, Lascorz J, B\u00f6hm B, et al. Genetic Variants of the IL-23R Pathway: Association with Psoriatic Arthritis and Psoriasis Vulgaris, but No Specific Risk Factor for Arthritis. J Invest Dermatol. 2009;129(2):355-358. d","DOI":"10.1038\/jid.2008.233"},{"key":"10.5826\/dpc.1603a6662_ref61","doi-asserted-by":"crossref","unstructured":"Capon F, Di Meglio P, Szaub J, et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet. 2007;122(2):201-206.","DOI":"10.1007\/s00439-007-0397-0"},{"key":"10.5826\/dpc.1603a6662_ref62","doi-asserted-by":"crossref","unstructured":"Francis L, McCluskey D, Ganier C, et al. Single-cell analysis of psoriasis resolution demonstrates an inflammatory fibroblast state targeted by IL-23 blockade. Nat Commun. 2024;15(1):913.","DOI":"10.1038\/s41467-024-44994-w"},{"key":"10.5826\/dpc.1603a6662_ref63","unstructured":"The RING ubiquitin E3 RNF114 interacts with A20 and modulates NF-\u03baB activity and T-cell activation | Cell Death & Disease. Accessed July 7, 2024. https:\/\/www.nature.com\/articles\/cddis2014366"},{"key":"10.5826\/dpc.1603a6662_ref64","doi-asserted-by":"crossref","unstructured":"Capon F, Bijlmakers MJ, Wolf N, et al. Identification of ZNF313\/RNF114 as a novel psoriasis susceptibility gene. Hum Mol Genet. 2008;17(13):1938-1945.","DOI":"10.1093\/hmg\/ddn091"},{"key":"10.5826\/dpc.1603a6662_ref65","doi-asserted-by":"crossref","unstructured":"Orsmond A, Bereza-Malcolm L, Lynch T, March L, Xue M. Skin Barrier Dysregulation in Psoriasis. Int J Mol Sci. 2021;22(19):10841.","DOI":"10.3390\/ijms221910841"},{"key":"10.5826\/dpc.1603a6662_ref66","doi-asserted-by":"crossref","unstructured":"Kim SA, Ryu YW, Kwon JI, Choe MS, Jung JW, Cho JW. Differential expression of cyclin D1, Ki\u201167, pRb, and p53 in psoriatic skin lesions and normal skin. Mol Med Rep. 2018;17(1):735-742.","DOI":"10.3892\/mmr.2017.8015"},{"key":"10.5826\/dpc.1603a6662_ref67","doi-asserted-by":"crossref","unstructured":"Cui W, Liu J, Kong S, et al. IL-17A and TNF-\u03b1-induced Dectin-1 expression may promote keratinocyte proliferation in psoriatic lesions. Eur J Dermatol. 2024;34(2):119-130.","DOI":"10.1684\/ejd.2024.4662"},{"key":"10.5826\/dpc.1603a6662_ref68","doi-asserted-by":"crossref","unstructured":"Richardson KC, Aubert A, Turner CT, et al. Granzyme K mediates IL-23-dependent inflammation and keratinocyte proliferation in psoriasis. Front Immunol. 2024;15:1398120.","DOI":"10.3389\/fimmu.2024.1398120"},{"key":"10.5826\/dpc.1603a6662_ref69","doi-asserted-by":"crossref","unstructured":"Halprin KM. Epidermal \u201cturnover time\u201d--a re-examination. Br J Dermatol. 1972;86(1):14-19.","DOI":"10.1111\/j.1365-2133.1972.tb01886.x"},{"key":"10.5826\/dpc.1603a6662_ref70","doi-asserted-by":"crossref","unstructured":"Mansbridge JN, Knapp AM, Strefling AM. Evidence for an alternative pathway of keratinocyte maturation in psoriasis from an antigen found in psoriatic but not normal epidermis. J Invest Dermatol. 1984;83(4):296-301.","DOI":"10.1111\/1523-1747.ep12340429"},{"key":"10.5826\/dpc.1603a6662_ref71","doi-asserted-by":"crossref","unstructured":"Trovato F, Ceccarelli S, Michelini S, et al. Advancements in Regenerative Medicine for Aesthetic Dermatology: A Comprehensive Review and Future Trends. Cosmetics. 2024;11(2):49.","DOI":"10.3390\/cosmetics11020049"},{"key":"10.5826\/dpc.1603a6662_ref72","doi-asserted-by":"crossref","unstructured":"Zhang X, Yin M, Zhang LJ. Keratin 6, 16 and 17-Critical Barrier Alarmin Molecules in Skin Wounds and Psoriasis. Cells. 2019;8(8):807.","DOI":"10.3390\/cells8080807"},{"key":"10.5826\/dpc.1603a6662_ref73","doi-asserted-by":"crossref","unstructured":"Jiang M, Fang H, Shao S, et al. Keratinocyte exosomes activate neutrophils and enhance skin inflammation in psoriasis. FASEB Journal. 2019;33(12):13241-13253.","DOI":"10.1096\/fj.201900642R"},{"key":"10.5826\/dpc.1603a6662_ref74","doi-asserted-by":"crossref","unstructured":"Zhang H, Hou W, Henrot L, et al. Modelling epidermis homoeostasis and psoriasis pathogenesis. J R Soc Interface. 2015;12(103):20141071.","DOI":"10.1098\/rsif.2014.1071"},{"key":"10.5826\/dpc.1603a6662_ref75","doi-asserted-by":"crossref","unstructured":"Roberson EDO, Bowcock AM. Psoriasis genetics: breaking the barrier. Trends Genet. 2010;26(9):415-423.","DOI":"10.1016\/j.tig.2010.06.006"},{"key":"10.5826\/dpc.1603a6662_ref76","doi-asserted-by":"crossref","unstructured":"Trujillo-Paez JV, Peng G, Le Thanh Nguyen H, et al. Calcitriol modulates epidermal tight junction barrier function in human keratinocytes. J Dermatol Sci. 2024;114(1):13-23.","DOI":"10.1016\/j.jdermsci.2024.02.001"},{"key":"10.5826\/dpc.1603a6662_ref77","unstructured":"Analysis of protein-protein interaction between late cornified envelope proteins and corneodesmosin - PubMed. Accessed July 14, 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/25078048\/"},{"key":"10.5826\/dpc.1603a6662_ref78","doi-asserted-by":"crossref","unstructured":"Sato Y, Ogawa E, Okuyama R. Role of Innate Immune Cells in Psoriasis. International Journal of Molecular Sciences. 2020;21(18):6604.","DOI":"10.3390\/ijms21186604"},{"key":"10.5826\/dpc.1603a6662_ref79","doi-asserted-by":"crossref","unstructured":"Christophers E, van de Kerkhof PCM. Severity, heterogeneity and systemic inflammation in psoriasis. J Eur Acad Dermatol Venereol. 2019;33(4):643-647.","DOI":"10.1111\/jdv.15339"},{"key":"10.5826\/dpc.1603a6662_ref80","doi-asserted-by":"crossref","unstructured":"Viguier M, Aubin F, Delaporte E, et al. Efficacy and Safety of Tumor Necrosis Factor Inhibitors in Acute Generalized Pustular Psoriasis. Archives of Dermatology. 2012;148(12):1423-1425.","DOI":"10.1001\/2013.jamadermatol.80"},{"key":"10.5826\/dpc.1603a6662_ref81","doi-asserted-by":"crossref","unstructured":"Dattola A, Zangrilli A, Bianchi L. Risankizumab for Plaque and Guttate Psoriasis in a Patient with IgA-Related Glomerulonephritis. Dermatol Pract Concept. 2021;11(4):e2021100.","DOI":"10.5826\/dpc.1104a100"},{"key":"10.5826\/dpc.1603a6662_ref82","doi-asserted-by":"crossref","unstructured":"Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52\u2010week, open\u2010label, phase 3 study (UNCOVER\u2010J). J Dermatol. 2017;44(4):355-362.","DOI":"10.1111\/1346-8138.13622"},{"key":"10.5826\/dpc.1603a6662_ref83","doi-asserted-by":"crossref","unstructured":"Morita A, Yamazaki F, Matsuyama T, et al. Adalimumab treatment in Japanese patients with generalized pustular psoriasis: Results of an open-label phase 3 study. The Journal of Dermatology. 2018;45(12):1371-1380.","DOI":"10.1111\/1346-8138.14664"},{"key":"10.5826\/dpc.1603a6662_ref84","doi-asserted-by":"crossref","unstructured":"Wang WM, Li F, Jin HZ. Role of interferon regulatory factor-mediated signaling in psoriasis. Int J Med Sci. 2021;18(16):3794-3799.","DOI":"10.7150\/ijms.61973"},{"key":"10.5826\/dpc.1603a6662_ref85","doi-asserted-by":"crossref","unstructured":"Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-\u03b1 production. J Exp Med. 2005;202(1):135-143.","DOI":"10.1084\/jem.20050500"},{"key":"10.5826\/dpc.1603a6662_ref86","doi-asserted-by":"crossref","unstructured":"Shaker OG, Moustafa W, Essmat S, Abdel-Halim M, El-Komy M. The role of interleukin-12 in the pathogenesis of psoriasis. Clinical Biochemistry. 2006;39(2):119-125. d","DOI":"10.1016\/j.clinbiochem.2005.11.008"},{"key":"10.5826\/dpc.1603a6662_ref87","unstructured":"Serum Levels of Tumor Necrosis Factor - alpha in Patients With Psoriasis - PMC. Accessed July 15, 2024. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9229364\/"},{"key":"10.5826\/dpc.1603a6662_ref88","unstructured":"Interleukin 12\/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn\u2019s disease - PMC. Accessed July 15, 2024. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6158482\/"},{"key":"10.5826\/dpc.1603a6662_ref89","doi-asserted-by":"crossref","unstructured":"Chu CC, Di Meglio P, Nestle FO. Harnessing dendritic cells in inflammatory skin diseases. Semin Immunol. 2011;23(1):28-41.","DOI":"10.1016\/j.smim.2011.01.006"},{"key":"10.5826\/dpc.1603a6662_ref90","doi-asserted-by":"crossref","unstructured":"Klechevsky E, Morita R, Liu M, et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity. 2008;29(3):497-510.","DOI":"10.1016\/j.immuni.2008.07.013"},{"key":"10.5826\/dpc.1603a6662_ref91","doi-asserted-by":"crossref","unstructured":"Sun X, Liu L, Wang J, et al. Targeting STING in dendritic cells alleviates psoriatic inflammation by suppressing IL-17A production. Cell Mol Immunol. 2024;21(7):738-751.","DOI":"10.1038\/s41423-024-01160-y"},{"key":"10.5826\/dpc.1603a6662_ref92","doi-asserted-by":"crossref","unstructured":"Kamata M, Tada Y. Dendritic Cells and Macrophages in the Pathogenesis of Psoriasis. Front Immunol. 2022;13.","DOI":"10.3389\/fimmu.2022.941071"},{"key":"10.5826\/dpc.1603a6662_ref93","doi-asserted-by":"crossref","unstructured":"Nazimek K, Bryniarski K. Macrophage Functions in Psoriasis: Lessons from Mouse Models. Int J Mol Sci. 2024;25(10):5306.","DOI":"10.3390\/ijms25105306"},{"key":"10.5826\/dpc.1603a6662_ref94","doi-asserted-by":"crossref","unstructured":"Lu Y, Zhu W, Zhang GX, et al. Adenosine A2A receptor activation regulates the M1 macrophages activation to initiate innate and adaptive immunity in psoriasis. Clin Immunol. Published online July 11, 2024:110309.","DOI":"10.1016\/j.clim.2024.110309"},{"key":"10.5826\/dpc.1603a6662_ref95","doi-asserted-by":"crossref","unstructured":"Teunissen MBM, Munneke JM, Bernink JH, et al. Composition of Innate Lymphoid Cell Subsets in the Human Skin: Enrichment of NCR+ ILC3 in Lesional Skin and Blood of Psoriasis Patients. J Invest Dermatol. 2014;134(9):2351-2360.","DOI":"10.1038\/jid.2014.146"},{"key":"10.5826\/dpc.1603a6662_ref96","unstructured":"Innate lymphoid cells--a proposal for uniform nomenclature - PubMed. Accessed July 14, 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/23348417\/"},{"key":"10.5826\/dpc.1603a6662_ref97","doi-asserted-by":"crossref","unstructured":"Blauvelt A, Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clinic Rev Allerg Immunol. 2018;55(3):379-390.","DOI":"10.1007\/s12016-018-8702-3"},{"key":"10.5826\/dpc.1603a6662_ref98","doi-asserted-by":"crossref","unstructured":"Sch\u00f6n MP. Adaptive and Innate Immunity in Psoriasis and Other Inflammatory Disorders. Front Immunol. 2019;10:1764.","DOI":"10.3389\/fimmu.2019.01764"},{"key":"10.5826\/dpc.1603a6662_ref99","doi-asserted-by":"crossref","unstructured":"Mosca M, Hong J, Hadeler E, Hakimi M, Liao W, Bhutani T. The Role of IL-17 Cytokines in Psoriasis. Immunotargets Ther. 2021;10:409-418.","DOI":"10.2147\/ITT.S240891"},{"key":"10.5826\/dpc.1603a6662_ref100","doi-asserted-by":"crossref","unstructured":"Cui W, Liu J, Kong S, et al. IL-17A and TNF-\u03b1-induced Dectin-1 expression may promote keratinocyte proliferation in psoriatic lesions. Eur J Dermatol. 2024;34(2):119-130.","DOI":"10.1684\/ejd.2024.4662"},{"key":"10.5826\/dpc.1603a6662_ref101","unstructured":"Frontiers | Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies. Accessed July 17, 2024. https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2023.1186455\/full"},{"key":"10.5826\/dpc.1603a6662_ref102","doi-asserted-by":"crossref","unstructured":"Boonpethkaew S, Meephansan J, Jumlongpim O, et al. Transcriptomic Profiling of Peripheral Edge of Lesions to Elucidate the Pathogenesis of Psoriasis Vulgaris. Int J Mol Sci. 2022;23(9):4983.","DOI":"10.3390\/ijms23094983"},{"key":"10.5826\/dpc.1603a6662_ref103","unstructured":"IL-17D-induced inhibition of DDX5 expression in keratinocytes amplifies IL-36R-mediated skin inflammation - PubMed. Accessed July 17, 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/36271146\/"},{"key":"10.5826\/dpc.1603a6662_ref104","doi-asserted-by":"crossref","unstructured":"Brunasso AMG, Massone C. Recent advances in palmoplantar pustulosis. Fac Rev. 2021;10:62.","DOI":"10.12703\/r\/10-62"},{"key":"10.5826\/dpc.1603a6662_ref105","doi-asserted-by":"crossref","unstructured":"Reich K, Cullen E, Weinberg M. Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence? Br J Dermatol. 2022;187(4):591-593.","DOI":"10.1111\/bjd.21617"},{"key":"10.5826\/dpc.1603a6662_ref106","doi-asserted-by":"crossref","unstructured":"Griffiths CEM, van de Kerkhof P, Czarnecka-Operacz M. Psoriasis and Atopic Dermatitis. Dermatol Ther (Heidelb). 2017;7(Suppl 1):31-41.","DOI":"10.1007\/s13555-016-0167-9"},{"key":"10.5826\/dpc.1603a6662_ref107","doi-asserted-by":"crossref","unstructured":"Palmer CNA, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441-446.","DOI":"10.1038\/ng1767"},{"key":"10.5826\/dpc.1603a6662_ref108","doi-asserted-by":"crossref","unstructured":"Cabanillas B, Novak N. Atopic dermatitis and filaggrin. Curr Opin Immunol. 2016;42:1-8.","DOI":"10.1016\/j.coi.2016.05.002"},{"key":"10.5826\/dpc.1603a6662_ref109","doi-asserted-by":"crossref","unstructured":"Edslev SM, Agner T, Andersen PS. Skin Microbiome in Atopic Dermatitis. Acta Derm Venereol. 2020;100(12):adv00164.","DOI":"10.2340\/00015555-3514"},{"key":"10.5826\/dpc.1603a6662_ref110","doi-asserted-by":"crossref","unstructured":"Gautam Y, Satish L, Ramirez S, et al. Joint genotype and ancestry analysis identify novel loci associated with atopic dermatitis in African American population. Human Genetics and Genomics Advances. 2024;5(4):100350.","DOI":"10.1016\/j.xhgg.2024.100350"},{"key":"10.5826\/dpc.1603a6662_ref111","doi-asserted-by":"crossref","unstructured":"\u010cepelak I, Dodig S, Pavi\u0107 I. Filaggrin and atopic march. Biochem med (Online). 2019;29(2):214-227.","DOI":"10.11613\/BM.2019.020501"},{"key":"10.5826\/dpc.1603a6662_ref112","unstructured":"Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-351. d"},{"key":"10.5826\/dpc.1603a6662_ref113","doi-asserted-by":"crossref","unstructured":"Winge MCG, Bilcha KD, Lied\u00e9n A, et al. Novel filaggrin mutation but no other loss-of-function variants found in Ethiopian patients with atopic dermatitis. Br J Dermatol. 2011;165(5):1074-1080.","DOI":"10.1111\/j.1365-2133.2011.10475.x"},{"key":"10.5826\/dpc.1603a6662_ref114","doi-asserted-by":"crossref","unstructured":"Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2009;124(3 Suppl 2):R7-R12.","DOI":"10.1016\/j.jaci.2009.07.012"},{"key":"10.5826\/dpc.1603a6662_ref115","unstructured":"IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion - PubMed. Accessed October 7, 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/22229441\/"},{"key":"10.5826\/dpc.1603a6662_ref116","doi-asserted-by":"crossref","unstructured":"Drislane C, Irvine AD. The role of filaggrin in atopic dermatitis and allergic disease. Ann Allergy Asthma Immunol. 2020;124(1):36-43.","DOI":"10.1016\/j.anai.2019.10.008"},{"key":"10.5826\/dpc.1603a6662_ref117","doi-asserted-by":"crossref","unstructured":"Henderson J, Northstone K, Lee SP, et al. The burden of disease associated with filaggrin mutations: a population-based, longitudinal birth cohort study. J Allergy Clin Immunol. 2008;121(4):872-877.e9.","DOI":"10.1016\/j.jaci.2008.01.026"},{"key":"10.5826\/dpc.1603a6662_ref118","doi-asserted-by":"crossref","unstructured":"Szegedi A. Filaggrin mutations in early- and late-onset atopic dermatitis. Br J Dermatol. 2015;172(2):320-321.","DOI":"10.1111\/bjd.13534"},{"key":"10.5826\/dpc.1603a6662_ref119","doi-asserted-by":"crossref","unstructured":"McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol. 2013;131(2):280-291.","DOI":"10.1016\/j.jaci.2012.12.668"},{"key":"10.5826\/dpc.1603a6662_ref120","doi-asserted-by":"crossref","unstructured":"Jaworek AK, Szafraniec K, Zuber Z, Wojas-Pelc A, Jaworek J. Interleukin 25, thymic stromal lymphopoietin and house dust mites in pathogenesis of atopic dermatitis. J Physiol Pharmacol. 2020;71(2).","DOI":"10.1007\/5584_2020_548"},{"key":"10.5826\/dpc.1603a6662_ref121","doi-asserted-by":"crossref","unstructured":"Acevedo N, Benfeitas R, Katayama S, et al. Epigenetic alterations in skin homing CD4+CLA+ T cells of atopic dermatitis patients. Sci Rep. 2020;10(1):18020.","DOI":"10.1038\/s41598-020-74798-z"},{"key":"10.5826\/dpc.1603a6662_ref122","doi-asserted-by":"crossref","unstructured":"Zhou S, Li Q, Wu H, Lu Q. The pathogenic role of innate lymphoid cells in autoimmune-related and inflammatory skin diseases. Cell Mol Immunol. 2020;17(4):335-346.","DOI":"10.1038\/s41423-020-0399-6"},{"key":"10.5826\/dpc.1603a6662_ref123","doi-asserted-by":"crossref","unstructured":"Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1-11.","DOI":"10.1016\/j.jaci.2018.10.032"},{"key":"10.5826\/dpc.1603a6662_ref124","doi-asserted-by":"crossref","unstructured":"Chiricozzi A, Maurelli M, Peris K, Girolomoni G. Targeting IL-4 for the Treatment of Atopic Dermatitis. ITT. 2020;Volume 9:151-156.","DOI":"10.2147\/ITT.S260370"},{"key":"10.5826\/dpc.1603a6662_ref125","doi-asserted-by":"crossref","unstructured":"Napolitano M, Di Vico F, Ruggiero A, Fabbrocini G, Patruno C. The hidden sentinel of the skin: An overview on the role of interleukin-13 in atopic dermatitis. Front Med. 2023;10:1165098.","DOI":"10.3389\/fmed.2023.1165098"},{"key":"10.5826\/dpc.1603a6662_ref126","doi-asserted-by":"crossref","unstructured":"Orfali RL, Aoki V. Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis. Pharmaceutics. 2023;15(2):577.","DOI":"10.3390\/pharmaceutics15020577"},{"key":"10.5826\/dpc.1603a6662_ref127","doi-asserted-by":"crossref","unstructured":"Agrawal R, Woodfolk JA. Skin Barrier Defects in Atopic Dermatitis. Curr Allergy Asthma Rep. 2014;14(5):433.","DOI":"10.1007\/s11882-014-0433-9"},{"key":"10.5826\/dpc.1603a6662_ref128","doi-asserted-by":"crossref","unstructured":"Criado PR, Miot HA, Bueno-Filho R, Ianhez M, Criado RFJ, de Castro CCS. Update on the pathogenesis of atopic dermatitis. Anais Brasileiros de Dermatologia. Published online August 12, 2024.","DOI":"10.1016\/j.abd.2024.06.001"},{"key":"10.5826\/dpc.1603a6662_ref129","doi-asserted-by":"crossref","unstructured":"J N, A B, I F. Lipid Alterations and Metabolism Disturbances in Selected Inflammatory Skin Diseases. International journal of molecular sciences. 2023;24(8).","DOI":"10.3390\/ijms24087053"},{"key":"10.5826\/dpc.1603a6662_ref130","doi-asserted-by":"crossref","unstructured":"Recent Advancements in the Atopic Dermatitis Mechanism. Accessed October 14, 2024. https:\/\/www.imrpress.com\/journal\/FBL\/29\/2\/10.31083\/j.fbl2902084","DOI":"10.31083\/j.fbl2902084"},{"key":"10.5826\/dpc.1603a6662_ref131","unstructured":"The exposome and health: Where chemistry meets biology - PubMed. Accessed October 14, 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/31974245\/"},{"key":"10.5826\/dpc.1603a6662_ref132","doi-asserted-by":"crossref","unstructured":"Dainichi T, Kitoh A, Otsuka A, et al. The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis. Nat Immunol. 2018;19(12):1286-1298.","DOI":"10.1038\/s41590-018-0256-2"},{"key":"10.5826\/dpc.1603a6662_ref133","doi-asserted-by":"crossref","unstructured":"Sugaya M. The Role of Th17-Related Cytokines in Atopic Dermatitis. International Journal of Molecular Sciences. 2020;21(4):1314. d","DOI":"10.3390\/ijms21041314"},{"key":"10.5826\/dpc.1603a6662_ref134","unstructured":"An Interleukin-25-Mediated Autoregulatory Circuit in Keratinocytes Plays a Pivotal Role in Psoriatic Skin Inflammation: Immunity. Accessed October 14, 2024. https:\/\/www.cell.com\/immunity\/fulltext\/S1074-7613(18)30116X?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS107476131830116X%3Fshowall%3Dtrue"},{"key":"10.5826\/dpc.1603a6662_ref135","doi-asserted-by":"crossref","unstructured":"Guttman-Yassky E, Krueger JG. Atopic dermatitis and psoriasis: two different immune diseases or one spectrum? Curr Opin Immunol. 2017;48:68-73.","DOI":"10.1016\/j.coi.2017.08.008"},{"key":"10.5826\/dpc.1603a6662_ref136","doi-asserted-by":"crossref","unstructured":"Chen Y, Peng C, Zhu L, et al. Atopic Dermatitis and Psoriasis: Similarities and Differences in Metabolism and Microbiome. Clinic Rev Allerg Immunol. 2024;66(3):294-315.","DOI":"10.1007\/s12016-024-08995-3"},{"key":"10.5826\/dpc.1603a6662_ref137","doi-asserted-by":"crossref","unstructured":"Tong X, Kim SH, Che L, Park J, Lee J, Kim TG. Foxp3+ Treg control allergic skin inflammation by restricting IFN-\u03b3-driven neutrophilic infiltration and NETosis. J Dermatol Sci. 2024:S0923-1811(24)00092-6.","DOI":"10.1016\/j.jdermsci.2024.05.002"},{"key":"10.5826\/dpc.1603a6662_ref138","doi-asserted-by":"crossref","unstructured":"Aguwa C, Enwereji N, Santiago S, et al. Targeting dysbiosis in psoriasis, atopic dermatitis, and hidradenitis suppurativa: the gut-skin axis and microbiome-directed therapy. Clin Dermatol. 2023;41(5):640-649.","DOI":"10.1016\/j.clindermatol.2023.09.019"},{"key":"10.5826\/dpc.1603a6662_ref139","doi-asserted-by":"crossref","unstructured":"\u0160uler Baglama \u0160, Tr\u010dko K. Skin and gut microbiota dysbiosis in autoimmune and inflammatory skin diseases. Acta Dermatovenerol Alp Pannonica Adriat. 2022;31(3):105-109.","DOI":"10.15570\/actaapa.2022.16"},{"key":"10.5826\/dpc.1603a6662_ref140","unstructured":"Diet, Gut Microbiota, and Obesity: Links with Host Genetics and Epigenetics and Potential Applications - PubMed. Accessed July 20, 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/30721960\/"},{"key":"10.5826\/dpc.1603a6662_ref141","unstructured":"Mechanisms of microbe-immune system dialogue within the skin | Genes & Immunity. Accessed July 20, 2024. https:\/\/www.nature.com\/articles\/s41435-021-00133-9"},{"key":"10.5826\/dpc.1603a6662_ref142","doi-asserted-by":"crossref","unstructured":"Zhu Y, Yu X, Cheng G. Human skin bacterial microbiota homeostasis: A delicate balance between health and disease. mLife. 2023;2(2):107-120.","DOI":"10.1002\/mlf2.12064"},{"key":"10.5826\/dpc.1603a6662_ref143","unstructured":"Petersen EBM, Skov L, Thyssen JP, Jensen P. Role of the Gut Microbiota in Atopic Dermatitis: A Systematic Review. Acta Derm Venereol. 2019;99(1):5-11."},{"key":"10.5826\/dpc.1603a6662_ref144","doi-asserted-by":"crossref","unstructured":"Yerushalmi M, Elalouf O, Anderson M, Chandran V. The skin microbiome in psoriatic disease: A systematic review and critical appraisal. J Transl Autoimmun. 2019;2:100009.","DOI":"10.1016\/j.jtauto.2019.100009"},{"key":"10.5826\/dpc.1603a6662_ref145","doi-asserted-by":"crossref","unstructured":"Mahmud MR, Akter S, Tamanna SK, et al. Impact of gut microbiome on skin health: gut-skin axis observed through the lenses of therapeutics and skin diseases. Gut Microbes. 2022;14(1):2096995.","DOI":"10.1080\/19490976.2022.2096995"},{"key":"10.5826\/dpc.1603a6662_ref146","doi-asserted-by":"crossref","unstructured":"Harden JL, Krueger JG, Bowcock AM. The immunogenetics of Psoriasis: A comprehensive review. J Autoimmun. 2015;64:66-73.","DOI":"10.1016\/j.jaut.2015.07.008"}],"container-title":["Dermatology Practical &amp; Conceptual"],"original-title":[],"link":[{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/6662\/3943","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/6662\/3943","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:21:02Z","timestamp":1786123262000},"score":1,"resource":{"primary":{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/view\/6662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":146,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5826\/dpc.1603a6662","relation":{"has-manifestation":[{"id-type":"other","id":"1-84-6662-g3943","asserted-by":"subject"}],"is-part-of":[{"id-type":"doi","id":"10.5826\/dpc.1603a%a","asserted-by":"subject"}]},"ISSN":["2160-9381"],"issn-type":[{"value":"2160-9381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"8"}}